Richard S. Levy - 03 Nov 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
03 Nov 2023
Net transactions value
$0
Form type
4
Filing time
07 Nov 2023, 16:33:10 UTC
Previous filing
03 Jul 2023
Next filing
03 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +2,777 +56% 7,777 03 Nov 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Award $0 +2,777 $0.000000 2,777 03 Nov 2023 Class A Common Shares 2,777 Direct F1, F2
transaction KNSA Restricted Share Units Options Exercise $0 -2,777 -100% $0.000000* 0 03 Nov 2023 Class A Common Shares 2,777 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vested immediately upon grant on November 3, 2023; there was no expiration date for the RSUs.